Elsevier Pharma & Life Sciences Solutions’ Post

What is cost costing you? As the pressure cooker of budget cuts starts to filter into planning decisions, our pharma clients are increasingly facing a difficult choice – prioritise needs or find cheaper alternatives. Choosing price invariably comes at the cost of quality. Poor quality undermines reliability, erodes trust and, ironically, often means paying someone else to fix it. Whether it’s uninspiring messaging, lacklustre materials or useless metrics, a true med comms partner can get to the root of the problem to ensure client content resonates with their audience. It doesn’t always have to be flashy or complicated, something as simple as asking the right questions at an advisory board, inviting the right speaker to your symposium, or taking a fresh perspective on a creative campaign can make the world of difference. We value working with our med comms clients to understand their needs and come up with bespoke solutions that work for everyone. We understand the importance of long-term partnership, sharing goals and working in synergy. And we get it right first time. Because when you prioritise partnership, quality becomes a given. Have you been burned by prioritising cost? Get in touch to see how we can help! https://loom.ly/bib1Kkg #MedComms #HealthcareCommunications

Gain a competitive edge with expert insights from Experts Advice! Connect with us now! #HealthcareExperts #MarketEntry #HealthTech #ExpertsAdvice

🚀 Boost your market entry with insights from Healthcare Experts! 🚀 Tap into our network of medical KOLs, regulatory experts and market access experts to gain insights. Don't navigate the healthcare market alone. Partner with QualWorld's Experts Advice for expert guidance! #HealthcareExperts #MarketEntry #HealthTech #ExpertsAdvice

Unveiling Our Data-Driven Approach: Elevating Medical Affairs, Market Access, and Regulatory Affairs in BeNeLux 🚀Our cutting-edge data science capabilities decode complex scenarios, offering insights that drive informed decision-making. From navigating regulatory landscapes to optimizing market access strategies, our data-driven approach ensures precision and foresight. 💡Curious to see how we can elevate your goals? Schedule a free consultation through our website and let's embark on a journey where data meets innovation, shaping a brighter future for healthcare in BeNeLux. #DataScience #HealthcareInnovation #MedicalAffairs #MarketAccess #RegulatoryAffairs #BeNeLuxHealthcare #InnovateWithUs

Now that we’ve identified the need to look at healthcare data more holistically to unlock new insights for medical affairs and commercial teams, it’s time to tackle one of the biggest challenges: data silos. Examining where your pharma organization is at in terms of collaboration is a crucial step in determining areas for growth and improvement. Robert Stevens, Principal at RS CONSULTATIVE, LLC wraps up this week’s series with his thoughts on how collaboration can be a catalyst for success: #medicalaffairs #healthcaredata

Historically, the R&D function has been focused on generating the safety and efficacy data required for regulatory approval. But in today’s value-based marketplace, that’s not enough. In our article, we explain why having a clear economic and clinical value case is needed for manufacturers to successfully position their products for reimbursement, adoption, and continued access.

Revolutionize your clinical trials with IQVIA's Intelligent Document Review. Experience unprecedented efficiency and accuracy in document review, ensuring faster and more reliable outcomes. Learn more: https://bit.ly/47WQUds #DocumentReview #ClinicalDataAnalytics

📰 In the News: GCI Health's Global Chief Content Officer David Chadwick, is featured in MM+M's three-part series, "A Public Health Call to Arms: The Long Road to FDA's Misinformation Guidance." This must-read series breaks down the FDA's long-awaited guidance on how #pharmaceutical brands can address online #health #misinformation from digital creators. In the report, Chadwick offers critical insights for understanding and leveraging this new guidance to respond to misleading social media content. While acknowledging its limitations, he notes that it "... could be a difference-maker in terms of correcting the record in the interest of public health."   Thank you, MM+M and Marc Iskowitz, for this invaluable, in-depth reporting. It's a must read for health communicators. Check it out here. https://lnkd.in/gCgbVqxj

Just 2 days to go until our next Market Access webinar! Hear from our industry experts about how Real World Data can inform market access strategies and help companies successfully transition from clinical development to commercialization. Click below to find out more and register: https://lnkd.in/dnRT_JD7 #RealWorldData #MarketAccess #WithEveryPatient

Earlier this week, we shared why sponsors should consider prioritizing standardization across the #researchsites they work with. Learn more in our latest blog about the role sites can play in standardizing their processes and what changes can be made to ensure more efficient and compliant trials. #clinicaltrials #clinicalresearch #siteoperations